Free Trial
→ IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead? (From American Alternative) (Ad)tc pixel

ImmuPharma (LON:IMM) Shares Up 28.8% - Time to Buy?

Written by MarketBeat
September 14, 2025
ImmuPharma logo with Medical background

Key Points

  • ImmuPharma's share price surged by 28.8% to GBX 13.98 ($0.19) during Friday's trading, significantly boosted by a trading volume of approximately 44.7 million shares, a 451% increase from its average daily volume.
  • The company reported a negative EPS of GBX (0.38) in its last quarterly earnings, with analysts forecasting an EPS of -339.0000022 for the current fiscal year.
  • ImmuPharma specializes in developing peptide-based therapeutics, with its lead program, Lupuzor™, targeting autoimmune diseases and showing potential for therapeutic activity in related conditions.
  • MarketBeat previews the top five stocks to own by October 1st.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price was up 28.8% during trading on Friday . The company traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). Approximately 44,749,293 shares traded hands during trading, an increase of 451% from the average daily volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Price Performance

The stock has a fifty day moving average of GBX 2.88 and a 200 day moving average of GBX 2.86. The firm has a market capitalization of £69.86 million, a P/E ratio of -1,570.67 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Equities analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ImmuPharma Right Now?

Before you consider ImmuPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.

While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.